Division/Committee: [BIOT] Division of Biochemical Technology

Cell therapies have demonstrated their efficacy to treat or be curative in oncology and non-oncology applications. Multiple avenues have been explored in the cellular therapy space to increase the potency but also simplify the process of generating cell therapy products, for example CAR-T, TCR-based therapies, and other gene-edited cells such as engineered NKs. This session will encompass various aspects of cell therapy process development including new rapid manufacturing processes in the autologous and iPSC approaches in the allogeneic cell therapy manufacturing space. This would include advances in the isolation, expansion, gene modification, media optimization, process scale up, , analytics and characterization of cell-based therapy products. Topics covering the impact of clinical pre-treatments and the cellular heterogeneity of the starting material on drug product potency and some of the control strategies to reduce this impact are invited. Additionally, novel drug products, cryopreservation and delivery strategies for in vivo use along with improved or novel viral vector production systems will be included in this session. Papers relevant to these topics are highly encouraged, including those focusing on novel process improvements, control and optimization strategies, equipment and reagents design and characterization.

Caryn L Heldt

Professor, Michigan Technological University

Appearances